Bing

SEARCH HISTORY

United Therapeutics Corporation (Nasdaq: UTHR) announced that its Board has approved and declared a stock split. The stock split will be effected in the form of a stock dividend, in which one share of United Therapeutics common stock will be distributed ...
StreetInsider · 9/1/2009
UTHR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $120.0 million. UTHR has traded 789,085 shares today. UTHR is down 3% today. UTHR was up 28.5% yesterday. The strong earnings growth this …
The Street · 9/2/2014
United Therapeutics (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 2,592 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $155.32, for a total transaction of $402,589.44. Following the …
Intercooler · 3/4/2015
More from Bing News
Big-cap biotech and IBD 50 stock United Therapeutics (UTHR) missed analysts' Q1 estimates Tuesday as its drug sales came up short, sending the stock tumbling in early trading. United reported revenue of $327.5 million, up 13% from the year-earlier …
Investors Business Daily · ByAmy Reeves · 4/28/2015
This would appear to signify that the stock in its view is no longer cheap. Summary: UTHR is a financially-strong, free cash flow-positive biotech company focused on an important orphan disease, with an evolving focus in oncology. It is trading at a market ...
Seeking Alpha · 7/30/2013
Analyst Raj Mehra of Auriga USA maintains his "buy" rating on United Therapeutics (NASDAQ: UTHR), while raising his estimates for the company. The target price for UTHR has been raised from $54 to $70. According to Auriga USA, United …
Benzinga · ByMonica Gerson · 1/13/2010
United Therapeutics Corporation (UTHR - Analyst Report) is set to report first-quarter ... is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen.
ZACKS · 4/27/2015
Within this sub-industry, one stock that has been a strong performer this Fall is United Therapeutics Corp (UTHR). Ever since August 29th when a US District Court judge made a favorable ruling on patents over the Remodulin drug, UTHR has been on fire.
Stockhouse · 10/21/2014
What: Shares of United Therapeutics (NASDAQ: UTHR ) , a biopharmaceutical company that develops ... make up for the eventual loss of exclusivity on Remodulin, then chasing the stock higher after today may not be the best idea. United Therapeutics may ...
The Motley Fool · BySean Williams · 8/30/2014
United Therapeutics Corporation (UTHR) experienced unusually high volume on Apr. 28, as the stock lost 5.17% to a closing price of $163.31. The stock saw 2.35 million shares trade hands over the course of the day on 23,279 trades. Given that the …
Equities · 4/29/2015